spacer
home > ebr > summer 2017 > upcycling genomics
PUBLICATIONS
European Biopharmaceutical Review

Upcycling Genomics

Gene therapies have taken centre stage in the medical field and interest is growing rapidly. For the first time, people can hope for a true cure of heritable disabilities by accessing a patient’s genome, as opposed to being treated only symptomatically, and any acquired pathologies with genetic elements are part of this development. HIV, for example, ‘hides’ in blood cells by integrating into the host’s genome, making it nearly impossible to remove from the system without genetic means. Asthma, arthritis, hypertension and many forms of cancers are in part caused by environmental factors that throw our genetic or epi-genetic makeup out of whack.

Of course, the application of genetic tools to patients is a controversial issue, and the backlash of early trials gone wrong in the 1990s severely dampened the whole, a setback that would be felt for over 10 years in the research community. With the number of clinical studies slumping and little growth for a decade, the concurrent rise of improved gene tools, paired with a much deeper understanding of the mechanisms underlying gene delivery, prepared a veritable rebirth of this field.

Following the rise of CRISPR/Cas9 technologies, the number of therapeutic strategies has become as plentiful as the range of human afflictions. This new shift towards gene therapy brings a measurable need for the optimisation of gene delivery strategies to enable practitioners to better transport their candidate constructs in a more targeted therapeutic context. While systemic applications favour the development of adeno-associated virus vector systems, highly efficient lentiviral vectors stand out as the system of choice for ex vivo therapies of hematopoietic cells (HCs) and hematopoietic stem cells (HSCs).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Franziska C Ruf is Senior Key Accounts Manager at SIRION Biotech with strong experience in molecular and cellular biology and her immunologic and hematopoietic background. Franziska worked as Project Coordinator and a Post-Doctoral Researcher in the Department of Hematology and Oncology at Klinikum rechts der Isar, Technical University Munich, Germany, where she also received her PhD in the Laboratory of Stem Cell Physiology.
spacer
Dr Franziska C Ruf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement